MedPath

江苏天士力帝益药业有限公司

Ownership
-
Established
1999-03-24
Employees
-
Market Cap
-
Website
http://www.taslydiyi.com

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

135

NMPA:135

Drug Approvals

Torasemide Injection

Product Name
托拉塞米注射液
Approval Number
国药准字H20254225
Approval Date
May 20, 2025
NMPA

Torasemide Injection

Product Name
托拉塞米注射液
Approval Number
国药准字H20254226
Approval Date
May 20, 2025
NMPA

Baclofen Oral Solution

Product Name
巴氯芬口服溶液
Approval Number
国药准字H20249626
Approval Date
Dec 1, 2024
NMPA

Procaterol Hydrochloride Oral Solution

Product Name
盐酸丙卡特罗口服溶液
Approval Number
国药准字H20244723
Approval Date
Aug 27, 2024
NMPA

Rivaroxaban Tablets

Product Name
利伐沙班片
Approval Number
国药准字H20247183
Approval Date
Aug 5, 2024
NMPA

Dapoxetine Hydrochloride Tablets

Product Name
盐酸达泊西汀片
Approval Number
国药准字H20244358
Approval Date
Jun 28, 2024
NMPA

Dapoxetine Hydrochloride Tablets

Product Name
盐酸达泊西汀片
Approval Number
国药准字H20244359
Approval Date
Jun 28, 2024
NMPA

Dexzopiclone Tablets

Product Name
文飞
Approval Number
国药准字H20090209
Approval Date
Nov 7, 2023
NMPA

Rivaroxaban Tablets

Product Name
利伐沙班片
Approval Number
国药准字H20233999
Approval Date
Aug 1, 2023
NMPA

Rivaroxaban Tablets

Product Name
利伐沙班片
Approval Number
国药准字H20234000
Approval Date
Aug 1, 2023
NMPA
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 14
  • Next

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.